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Table S1. Diseases and disorders that could be treated by targeting ECS proteins.1
Protein Ligand type Remarks Evidence References
Pain
CB1 Agonist














AEA reuptake proteinsInhibitor [11]
ABHD6 Inhibitor [11]
TRPV1 Antagonist [11,12]









FAAH Enhancer FAAH in basolateral complex of amygdala
Limited evidence
[18]














Preferable neutral antagonist or
































CB1 Antagonist Focal cortical dysplasia [47]
Inflammatory and autoimmune diseases
CB2 Agonist Inflammatory diseases
Well grounded
[48–52]
CB2 Antagonist Immunoparalysis, renal fibrosis [53,54]
FAAH Inhibitor [55–57]
PPARγ Agonist [51,52]
















GPR18 Agonist Limited evidence [71]
Diabetes











GPR119 Agonist Limited evidence [82]
Hypertension















CB2 Agonist Deleterious effect in myocardial infraction
Limited evidence
[91,92]












NAAA Inhibitor Limited evidence [108]
Respiratory disorders
CB1 Agonist Well grounded [109]
Gastroenterology















Potential use in erectile dysfunctions,
preferable peripheral antagonist/inverse agonist
Limited evidence [116]
Dermatology
CB1 Agonist Anti-fibrotic effect, hair growth
Well grounded
[117,118]
CB1 Antagonist Anti-inflammatory [117,118]
CB2 Agonist Anti-acne, anti-seborrhea effect [117,118]
CB2 Antagonist Anti-dryness, anti-inflammatory, anti-fibrotic effect [117,118]
eCB reuptake proteins Inhibitor In conditions with inflammation and dryness Limited evidence [119]
Genetic disorders
CB1 Antagonist Duchenne muscular dystrophy Limited evidence [120]
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Table S2. Possible indications for activation or inhibition of the proteins of ECS.2


















Emesis and nausea [110,122]
Anorexia and weight loss [123]



























Inflammatory bowel disease [112]









Disbalance in the kidney redox system






































PPARγ Agonist Systemic sclerosis [51,52]























The following abbreviations are used in the Supplementary Materials:4
5
ABHD6α/β hydrolase domain 6
AEA N-arachidonoylethanolamine (anandamide)
CB1 cannabinoid receptor type 1
CB2 cannabinoid receptor type 2
eCB endocannabinoid
FAAH fatty acid amide hydrolase
GPR18 G protein-coupled receptor 18
GPR55 G protein-coupled receptor 55
GPR119G protein-coupled receptor 119
MAGL monoacylglycerol lipase
NAAA N-acylethanolamine acid amidase
PAM positive allosteric modulator
PPARα peroxisome proliferator-activated receptor α
PPARγ peroxisome proliferator-activated receptor γ
TRPV1 transient receptor potential vanilloid type 1 channel
6
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